Gilead Sciences Amends Officer and Director Filings
Ticker: GILD · Form: 8-K/A · Filed: Dec 13, 2024 · CIK: 882095
| Field | Detail |
|---|---|
| Company | Gilead Sciences, INC. (GILD) |
| Form Type | 8-K/A |
| Filed Date | Dec 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, corporate-governance, executive-compensation
Related Tickers: GILD
TL;DR
Gilead Sciences 8-K/A filed: amendments to officer/director changes and compensation. No new financials.
AI Summary
Gilead Sciences, Inc. filed an 8-K/A on December 13, 2024, to amend a previous filing from July 17, 2024. The amendment pertains to the departure of certain officers and the election of directors, as well as compensatory arrangements for specific officers. The filing does not appear to involve any new financial statements or exhibits.
Why It Matters
This filing clarifies changes in Gilead's corporate governance and executive compensation structure, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: low — The filing is an amendment to previous disclosures regarding corporate governance and executive compensation, not a new material event.
Key Players & Entities
- GILEAD SCIENCES, INC. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- July 17, 2024 (date) — Date of earliest event reported in original filing
- December 13, 2024 (date) — Filing date of the 8-K/A
FAQ
What specific items are being amended in this 8-K/A filing?
This 8-K/A amends Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers) and Item 5.07 (Regulation FD Disclosure) of the original filing.
What was the original filing date that this 8-K/A amends?
This 8-K/A amends a filing originally reported on July 17, 2024.
Does this amendment include any new financial statements or exhibits?
No, the filing explicitly states that no new financial statements or exhibits are being filed as part of this amendment.
What is the primary purpose of an 8-K/A filing?
An 8-K/A is filed to amend a previously filed Current Report on Form 8-K to correct or supplement information.
What is the principal business address of Gilead Sciences, Inc.?
The principal executive offices are located at 333 Lakeside Drive, Foster City, California 94404.
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-12-12 17:38:27
Key Financial Figures
- $0.001 — h registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Se
Filing Documents
- tm2430889d1_8ka.htm (8-K/A) — 28KB
- tm2430889d1_ex99-1.htm (EX-99.1) — 10KB
- tm2430889d1_ex99-1img001.jpg (GRAPHIC) — 10KB
- 0001104659-24-128088.txt ( ) — 223KB
- gild-20240717.xsd (EX-101.SCH) — 3KB
- gild-20240717_lab.xml (EX-101.LAB) — 33KB
- gild-20240717_pre.xml (EX-101.PRE) — 22KB
- tm2430889d1_8ka_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously announced by Gilead Sciences, Inc., a Delaware corporation (the "Company"), Merdad V. Parsey, M.D., Ph.D., the Company's Chief Medical Officer, will leave the Company following a transition. On December 12, 2024, the Company announced Dietmar Berger, M.D., Ph.D., will succeed Dr. Parsey as Chief Medical Officer, effective as of January 2, 2025. Dr. Parsey has agreed to remain with the Company as a Senior Advisor through the first quarter of 2025, at which point his employment with the Company will be terminated without cause.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d)Exhibits The following exhibit 99.1 is furnished pursuant to this Item 9.01. Exhibit Number Description 99.1 Press Release by Gilead Sciences, Inc. dated December 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GILEAD SCIENCES, INC. (Registrant) /s/ Deborah H. Telman Deborah H. Telman EVP, Corporate Affairs, General Counsel and Corporate Secretary Date: December 12, 2024